The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.
The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.
The user has been treating hair loss with finasteride, dutasteride, oral minoxidil, and pyrilutamide for several years without success and is experiencing an inflamed scalp, possibly due to seborrheic dermatitis. They are seeking advice on additional treatments after these methods failed to improve their condition.
A user is seeking a brush for dry, thick hair that can effectively stimulate the scalp and distribute natural oils. Another user recommends a "wet" brand detangling brush that works well for their coarse, dry hair and helps distribute argan oil to the scalp.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.
PRP is not a cure for baldness but can support hair growth, though it requires ongoing sessions and is costly. Minoxidil and Finasteride are commonly used treatments, but results vary.
A 21-year-old individual questioning the safety and potential side effects of using Dutasteride for hair loss, after Finasteride and RU58841 had limited effect. The responses vary, with some users suggesting it's safe and others advising to check hormone levels before proceeding.
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.
A user who has been using Pyrilutamide for 19 days, experiencing some hair thickening in the right temple and crown area but also having ball ache after microneedling; other users offer advice, caution and skepticism as to whether results can be seen in such a short time.
The user is frustrated with ongoing hair loss despite using treatments like finasteride, dutasteride, minoxidil, RU58841, and others. They express concern over the lack of improvement in hair density and the emotional toll it takes.
The user is experiencing significant hair shedding after starting RU58841, despite using dutasteride and oral minoxidil for over a year without stabilization. Others suggest continuing the treatment as shedding can be a normal phase, but caution that RU58841 is unpredictable.
The conversation is about a hair transplant operation video by a clinic owner, with comments suggesting it's staged for marketing and criticizing the unrealistic hairline created. Some users question the necessity of the transplant for the individual featured.
A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.
27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.
The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.
A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
A drug that regrows body parts, but not hair, sparking debate on hair loss treatments. Discussions include the use of finasteride, dutasteride, and the potential for new methods to restore hair.